Evidence map›Paper›PMID 38383124›Full record

ArticleBMJ case reports2024

Heterozygous desmoplakin (

Akshay Mathavan, Urszula Krekora, Miguel Belaunzaran Dominguez, Akash Mathavan

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Gene Therapy TargetingMedComm · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Akshay MathavanInternal Medicine, University of Florida, Gainesville, Florida, USA.ORCID http://orcid.org/0000-0002-3850-834X
Urszula KrekoraCollege of Medicine, University of Central Florida, Orlando, Florida, USA.
Miguel Belaunzaran DominguezInternal Medicine, University of Florida, Gainesville, Florida, USA.
Akash MathavanInternal Medicine, University of Florida, Gainesville, Florida, USA amathavan2496@ufl.edu.ORCID http://orcid.org/0000-0003-3496-2542
University of Florida · USUniversity of Central Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arrhythmogenic cardiomyopathy is a non-ischaemic cardiomyopathy characterised by the presence of myocardial dysfunction and inherited conduction disease that predisposes patients to malignant ventricular arrhythmias and sudden cardiac death. There is a growing awareness of the diverse phenotypic presentation of arrhythmogenic cardiomyopathy, which may demonstrate preferential involvement of the left, right or both ventricles. A subset of arrhythmogenic cardiomyopathy may be due to mutations of desmosomes, intercellular junctions of the myocardium that promote structural and electrical integrity. Mutations of desmoplakin, encoded by the

Indexed as

Arrhythmogenic Right Ventricular DysplasiaCardiomyopathiesTachycardia, VentricularDesmoplakinsHumansMyocardiumDesmoplakinsarrhythmiasgeneticsheart failurepacing and electrophysiology

Identifiers

PMID38383124
PMCPMC10882317
OpenAlexW4392014916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.